医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Chiltern and Partners Hold Seminar at the British Embassy in Japan

2015年10月13日 PM09:00
このエントリーをはてなブックマークに追加


 

LONDON & WILMINGTON, N.C.

Chiltern, a leading, global contract research organization (CRO), hosted an industry seminar at the British Embassy in Tokyo, Japan, on Oct. 6, 2015, alongside Veras Research and LSK Global Pharma Services.

The event, “Exploring Options for Local and Global Outsourcing in the Pharmaceutical and Biotech Industries,” focused on development insights for oncology trials, other key therapeutic areas, medical devices and functional service provision relative to the Japanese market.

Chiltern has a long history of partnering with a significant number of Japanese companies, and its team members have regularly visited the embassy in Tokyo since 2003. The seminar supported Chiltern’s and Veras’ commitment to growing in Asia, with a specific focus in Japan.

“By working with Veras and LSK, we strengthen Chiltern’s already extensive footprint in Japan,” said Stuart McGuire, executive vice president, global business development, at Chiltern. “We are grateful for the support from UK Trade & Investment and the British Embassy in Tokyo for their part in helping us create such an exciting forum for discussion.”

McGuire co-hosted the event and was joined by other members of the Chiltern leadership team, including Nick Thornton, chairman, and Roger Hunter, executive vice president, scientific affairs and strategic development.

Chiltern has robust expertise in the conduct of global clinical trials, specifically in the fields of oncology, respiratory, anti-infectives, dermatology and ophthalmology, with special capabilities in clinical analytics and medical device and diagnostics. Its quality of service, value and global presence are important for many companies looking to involve Japan in their clinical development programs.

If you’d like more information on Chiltern’s capabilities in Japan, email Stuart.McGuire@Chiltern.com. Learn more about Chiltern’s services and its global reach by visiting Chiltern.com.

About Chiltern:

Chiltern is the leading, global mid-sized contract research organization that listens to client needs to deliver customized clinical development solutions. Chiltern’s team of more than 3,700 works across 47 countries to provide flexible, specialized services, with core competencies in Biopharma, Medical Device and Diagnostics, Oncology, Clinical Analytics and Source. Visit Chiltern.com to learn more about responsive solutions that are Designed Around You®.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151013005038/en/

CONTACT

SCORR Marketing
Lea Studer, +1 308-237-5567
lea@scorrmarketing.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • SpeeDx经销网络扩展至中东
  • SpeeDxの販売ネットワークが中東に拡大
  • P&G Sets New Goal to Deliver 25 Billion Liters of Clean Drinking Water to Families in Need Worldwide
  • Puma Biotechnology’s Licensing Partner Specialised Therapeutics Asia Receives Regulatory Approval to Commercialize NERLYNX® (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
  • Takeda Receives U.S. FDA Approval to Manufacture FLEXBUMIN® at New Plasma Manufacturing Facility near Covington, Georgia